5 Years of Leukemia Advances: A Timeline of FDA Approvals and What They Mean for Patients

If you or someone you love has leukemia, it helps to understand something up front: "leukemia" isn't one disease. Chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) are genetically and clinically very different cancers that happen to share a name. But looking at what the FDA has actually approved over the last five years shows the same underlying story playing out in all three — a drug proves itself in the hardest cases and earns approval there first, then either gets approved for earlier use or a completely new kind of drug is approved where nothing worked before. Every treatment below reached patients because it cleared that FDA approval bar, based on real trial data reviewed by the agency — not early promise or a company's own claims.

What Doctors Are Actually Working Toward

For most leukemias, the end goal isn't just "shrink the cancer for a while." It's one of two things: turn the disease into something a person can live with long-term on manageable treatment (the way CML has largely become), or push toward deep, lasting remissions that hold up for years without ongoing treatment (which AML and CLL are both edging closer to, mutation by mutation). Every FDA approval below is a documented step toward one of those two goals, for a specific group of patients — and each one only happened after the FDA reviewed clinical trial results and determined the benefit was real.

2021: A New Way to Attack CML When Older Drugs Stop Working

Since the early 2000s, CML has mostly been treated with pills called tyrosine kinase inhibitors (TKIs) — drugs like Gleevec (imatinib), Sprycel (dasatinib), and nilotinib that block the specific abnormal protein driving the cancer. These pills turned CML from a often-fatal disease into one many people live with for decades. But some patients' cancer becomes resistant to these drugs, or the side effects become too much to tolerate.

Scemblix (asciminib) arrived in 2021 as something genuinely new: instead of attacking the cancer-driving protein at the same spot every prior TKI targeted, it locks onto a completely different part of the protein — what scientists call a STAMP inhibitor. That difference matters practically: Scemblix can still work in patients whose CML has become resistant to two or more older TKIs, including a version specifically for a hard-to-treat resistance mutation called T315I. CML affects roughly 9,000 to 10,000 new patients a year in the U.S., and this gave a meaningful slice of them — those who'd run out of standard options — a genuine next step instead of a dead end.

2022: Proof That an Existing CLL Drug Actually Works Better, Plus a New AML Option

This is the year proof arrived, not just a new drug — sometimes what changes practice is showing an existing option beats another head-to-head, which changes what doctors reach for first. That's what happened in CLL, the most common form of leukemia in adults, with roughly 20,000 new cases diagnosed in the U.S. each year. The Phase 3 ALPINE trial directly compared Brukinsa (zanubrutinib) against Imbruvica (ibrutinib) — both BTK inhibitors, a class of pills that block a protein CLL cells need to survive and grow. Brukinsa won on how long patients stayed in remission, with meaningfully fewer heart-related side effects like irregular heartbeat. Dr. Jennifer Brown of Dana-Farber Cancer Institute, the trial's lead author, told CURE: "ALPINE is the first study to demonstrate progression-free survival superiority in a head-to-head comparison of BTK inhibitors in patients with relapsed or refractory CLL or SLL." That single trial shifted which BTK inhibitor many doctors now offer first.

The same year, Rezlidhia (olutasidenib) was approved for relapsed or refractory AML with an IDH1 gene mutation — a targeted pill for a molecularly defined subgroup of AML patients who previously had few options beyond chemotherapy.

2023: A Way Forward When CLL Stops Responding to BTK Inhibitors

Here's the problem BTK inhibitors created even as they helped so many people: once CLL becomes resistant to a covalent BTK inhibitor like Brukinsa or Calquence (acalabrutinib), doctors historically couldn't just switch to a different drug in that same class — the resistance usually blocked the whole category.

Jaypirca (pirtobrutinib) broke that pattern. It's a non-covalent BTK inhibitor, meaning it attaches to the same target protein in a different, more flexible way — one that can still work even after the cancer has adapted to escape covalent BTK inhibitors. Dr. Juan Alderuccio of Sylvester Comprehensive Cancer Center explained the significance to CURE in a 2023 interview: for patients who'd exhausted both BTK and BCL-2 inhibitor classes, this opened a door that had previously been closed.

2024: The First Entirely New Drug Class for Leukemia in Years, and CML's Earlier-Use Milestone

This was the year two very different stories landed at once. Revuforj (revumenib) became the first-ever menin inhibitor approved for any cancer — for relapsed or refractory acute leukemia with a KMT2A gene rearrangement, a high-risk genetic change found in both AML and acute lymphoblastic leukemia (ALL), in both children and adults. Dr. Eytan Stein of Memorial Sloan Kettering, who led the trial, described how differently this drug works compared to standard chemotherapy: instead of killing leukemia cells outright, it pushes the abnormal, immature cells to mature into normal, functioning blood cells. Among evaluable patients in the pivotal trial, roughly 30% achieved a complete remission — a real result for a group of heavily pretreated patients who'd had few other options.

That same year, Scemblix's approval expanded from previously treated CML patients to newly diagnosed ones — the first-line move that had been the goal since its 2021 debut, based on a trial showing 68% of Scemblix-treated patients reached a deep molecular response at 48 weeks, compared to 49% on standard treatment.

2025: A Common AML Mutation Gets Its First Targeted Drug, and Jaypirca Graduates to Full Approval

Revuforj's approval expanded again in 2025, this time to AML with an NPM1 gene mutation — the single most common genetic mutation in adult AML, found in roughly 30% of cases, far more prevalent than the KMT2A rearrangements it was first approved for. Between the two approved mutations, Revuforj can now potentially reach up to 40% of all AML patients, a dramatic jump in reach for a drug that didn't exist a year earlier.

Meanwhile, Jaypirca converted from its 2023 accelerated approval to full, traditional FDA approval for CLL and small lymphocytic lymphoma (SLL), based on confirmatory data (the BRUIN-CLL-321 trial) showing it improved how long patients stayed in remission compared to standard next-line options.

2026: A Chemo-Free Option for the AML Patients Who've Had the Fewest Choices

AML disproportionately affects older adults — the average age at diagnosis is 68 — and many of them simply can't tolerate the intensive, hospital-based chemotherapy that's been the backbone of AML treatment for decades. In 2026, an oral combination of Inqovi (decitabine and cedazuridine) with Venclexta (venetoclax) was approved specifically for newly diagnosed AML in adults 75 or older, or with health conditions that rule out intensive chemo. This gives one of AML's most underserved groups — patients who've historically been left out of aggressive treatment entirely — a real, at-home pill regimen instead of no good option at all.

What This Means Now, and How Many People It's Actually Reaching

To put real numbers on this: Revuforj alone can now potentially help up to 40% of the roughly 20,000 Americans diagnosed with AML each year — a group measured in the thousands who had no targeted option at all before 2024. Scemblix's move to first-line therapy means a much larger share of the 9,000-plus Americans diagnosed with CML annually can start on a drug built to avoid the resistance and side effects of older TKIs, rather than waiting to fail multiple prior treatments first. And Jaypirca's shift to full approval reflects real, lasting benefit confirmed in patients who'd already run out of both major CLL drug classes.

Menin inhibitors are a brand-new class with real room to grow. Revuforj went from covering one high-risk mutation to a second, far more common one, inside a single year — a sign this mechanism likely has more to offer than its first approval alone.

Resistance is increasingly treated as solvable, not a dead end. Jaypirca exists specifically because it works differently than the BTK inhibitors that came before it — a pattern worth watching as more leukemia patients develop resistance to first-generation targeted drugs.

Older and frailer patients are finally getting dedicated research attention. The 2026 Inqovi (decitabine and cedazuridine) plus Venclexta (venetoclax) approval targets exactly the population that's historically been excluded from AML drug trials because they can't tolerate intensive chemotherapy.

Questions worth asking your doctor:

• Has my leukemia been tested for all currently relevant mutations — including NPM1, KMT2A, and IDH1 for AML, or specific resistance patterns for CLL?
• If my current targeted therapy has stopped working, is there a next-generation option, like a non-covalent BTK inhibitor, built for that specific resistance?
• For CML patients: has my treatment plan been reviewed since newer options like Scemblix became available as first-line therapy?

None of this erases how hard a leukemia diagnosis is. But look at what actually happened in just five years: a cancer considered essentially untargetable got its first new drug class in years, a resistance pattern that used to be a dead end became something doctors could work around, and a group of patients who couldn't tolerate treatment at all finally got an option built for them. That pace hasn't slowed down — it's arguably accelerating, mutation by mutation. If your leukemia doesn't have a good answer today, the honest, evidence-backed reason for hope is that this field has a real track record of finding one within a few years, not decades.If you or someone you love has leukemia, it helps to understand something up front: "leukemia" isn't one disease. Chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) are genetically and clinically very different cancers that happen to share a name. But looking at what the FDA has actually approved over the last five years shows the same underlying story playing out in all three — a drug proves itself in the hardest cases and earns approval there first, then either gets approved for earlier use or a completely new kind of drug is approved where nothing worked before. Every treatment below reached patients because it cleared that FDA approval bar, based on real trial data reviewed by the agency — not early promise or a company's own claims.

For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.